Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Gut Vibes in Parkinson's Disease: The Microbiota‐Gut‐Brain Axis
Clara Bullich‐Vilarrubias, Ali Keshavarzian, Johan Garssen, et al.
Movement Disorders Clinical Practice (2019) Vol. 6, Iss. 8, pp. 639-651
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease
Velma T. E. Aho, Madelyn C. Houser, Pedro A. B. Pereira, et al.
Molecular Neurodegeneration (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 307
The Association Between the Gut Microbiota and Parkinson's Disease, a Meta-Analysis
Ting Shen, Yumei Yue, Tingting He, et al.
Frontiers in Aging Neuroscience (2021) Vol. 13
Open Access | Times Cited: 168
The microbiota–gut–brain axis: pathways to better brain health. Perspectives on what we know, what we need to investigate and how to put knowledge into practice
Anirikh Chakrabarti, Lucie Geurts, Lesley Hoyles, et al.
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 2
Open Access | Times Cited: 132
Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease
Manlian Zhu, Xia Liu, Yiru Ye, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 102
Neurodegenerative and Neurodevelopmental Diseases and the Gut-Brain Axis: The Potential of Therapeutic Targeting of the Microbiome
Brian Bicknell, Ann Liebert, Thomas J. Borody, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9577-9577
Open Access | Times Cited: 63
An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants
Deborah A. Hall, Robin M. Voigt, Thaisa M. Cantu-Jungles, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 57
Gastrodia elata polysaccharide alleviates Parkinson's disease via inhibiting apoptotic and inflammatory signaling pathways and modulating the gut microbiota
Qingxia Gan, Maoyao Peng, Haobo Wei, et al.
Food & Function (2024) Vol. 15, Iss. 6, pp. 2920-2938
Closed Access | Times Cited: 18
Epidemiology of Parkinson’s Disease: An Update
Juan R. Deliz, Caroline M. Tanner, Paulina González-Latapí
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 6, pp. 163-179
Closed Access | Times Cited: 16
Parkinson’s disease treatment: past, present, and future
John D. Elsworth
Journal of Neural Transmission (2020) Vol. 127, Iss. 5, pp. 785-791
Open Access | Times Cited: 76
Predicting Neurodegenerative Disease Using Prepathology Gut Microbiota Composition: a Longitudinal Study in Mice Modeling Alzheimer’s Disease Pathologies
Emily M. Borsom, Kathryn A Conn, Christopher R. Keefe, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 2
Open Access | Times Cited: 22
Dysbiosis of the gut microbiota and its effect on α-synuclein and prion protein misfolding: consequences for neurodegeneration
Nasir Uddin Mahbub, Md Minarul Islam, Seong‐Tshool Hong, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 14
Can microbiota gut-brain axis reverse neurodegenerative disorders in human?
Xingxing Yuan, Serge Yannick Ouédraogo, Modou Lamin Jammeh, et al.
Ageing Research Reviews (2025), pp. 102664-102664
Closed Access | Times Cited: 1
Sex Differences in the Gut-Brain Axis: Implications for Mental Health
Calliope Holingue, Alexa C. Budavari, Katrina Rodriguez, et al.
Current Psychiatry Reports (2020) Vol. 22, Iss. 12
Open Access | Times Cited: 68
Photobiomodulation for Parkinson’s Disease in Animal Models: A Systematic Review
Farzad Salehpour, Michael R. Hamblin
Biomolecules (2020) Vol. 10, Iss. 4, pp. 610-610
Open Access | Times Cited: 59
Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease
Jonas Ghyselinck, Lynn Verstrepen, Frédéric Moens, et al.
International Journal of Pharmaceutics X (2021) Vol. 3, pp. 100087-100087
Open Access | Times Cited: 46
Gut microbiome and Parkinson's disease: Perspective on pathogenesis and treatment
Safa Salim, Fatima Ahmad, Ayesha Banu, et al.
Journal of Advanced Research (2022) Vol. 50, pp. 83-105
Open Access | Times Cited: 34
The Gut Microbiome in Parkinson’s Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies
Michal Lubomski, Xiangnan Xu, Andrew Holmes, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 32
Gut microbial metabolites in Parkinson's disease: Association with lifestyle, disease characteristics, and treatment status
Robin M. Voigt, Zeneng Wang, J. Mark Brown, et al.
Neurobiology of Disease (2022) Vol. 170, pp. 105780-105780
Open Access | Times Cited: 28
Gut-to-Brain α-Synuclein Transmission in Parkinson’s Disease: Evidence for Prion-like Mechanisms
Merry Chen, Danielle E. Mor
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7205-7205
Open Access | Times Cited: 21
Overexpression of human alpha-Synuclein leads to dysregulated microbiome/metabolites with ageing in a rat model of Parkinson disease
Yogesh Singh, Christoph Trautwein, J. Romaní, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 17
What the Gut Tells the Brain—Is There a Link between Microbiota and Huntington’s Disease?
Dorota Wronka, Anna Karlik, Julia O. Misiorek, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4477-4477
Open Access | Times Cited: 16
Butyrate as a potential therapeutic agent for neurodegenerative disorders
Prapti Chakraborty, Hasinika K. A. H. Gamage, Angela S. Laird
Neurochemistry International (2024) Vol. 176, pp. 105745-105745
Closed Access | Times Cited: 6
Korean red ginseng suppresses 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced inflammation in the substantia nigra and colon
Hyongjun Jeon, Chang‐Hwan Bae, Yukyoung Lee, et al.
Brain Behavior and Immunity (2021) Vol. 94, pp. 410-423
Closed Access | Times Cited: 36
Dual-Hit Model of Parkinson’s Disease: Impact of Dysbiosis on 6-Hydroxydopamine-Insulted Mice—Neuroprotective and Anti-Inflammatory Effects of Butyrate
Carmen Avagliano, Lorena Coretti, Adriano Lama, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6367-6367
Open Access | Times Cited: 26
Parkinson’s disease and cancer: a systematic review and meta-analysis on the influence of lifestyle habits, genetic variants, and gender
Selene Joon Yan Lee, Jing Han Ng, Seyed Ehsan Saffari, et al.
Aging (2022) Vol. 14, Iss. 5, pp. 2148-2173
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top